From the Journals
Expert panel updates guidelines on antithrombotic therapy for AF
The new guidelines highlight 60 key recommendations from the 12-person expert panel.
We have updated our Privacy Policy. Please take the time to review
Conference Coverage
Synergy DES shines in acute MI
PARIS – Swedish registry report analyzes key clinical outcomes in more than 36,000 consecutive acute MI patients who received newer-generation...
Conference Coverage
How to identify DVT faster in pediatric osteomyelitis
MALMO, SWEDEN – Recognition of key risk factors warrants early screening ultrasound.
From the Journals
Obesity triples post-MI sudden cardiac death risk
The obesity paradox makes a showing in the risk of all-cause death.
From the Journals
New look at ATLAS suggests rivaroxaban may still have role in ACS
A reanalysis of the ATLAS ACS 2-TIMI 51 trial separated fatal and nonfatal events.
Conference Coverage
Amplatzer Amulet slashes stroke risk in A-fib
PARIS – “Given the high bleeding risk, single antiplatelet therapy seems to be a good option for these patients,” said Dr. Ulf Landmesser.
Conference Coverage
Design limitations may have compromised DVT intervention trial
WASHINGTON – The preferred evaluation – intravascular ultrasound – was not used.
News
First reversal agent for apixaban and rivaroxaban gets fast-track approval
Andexanet alfa approval puts factor Xa inhibitors in the same ballpark as dabigatran, reversible with idarucizumab.
Conference Coverage
Does warfarin cause acute kidney injury?
SAN DIEGO – Consider increased monitoring of renal function in certain patients.
From the Journals
Women’s representation in CV drug trials still lagging
We’ve come a long way in clinical trial representation of women, but there’s more work to do.
Conference Coverage
MI before age 50? Think familial hypercholesterolemia, substance abuse
More than one-third of patients with an MI before age 50 and an LDL cholesterol of at least 160 mg/dL meet criteria for FH.
Conference Coverage
Impaired kidney function no problem for dabigatran reversal
ORLANDO – Idarucizumab, reversal agent for the anticoagulant dabigatran, worked fine in patients with renal dysfunction.
Conference Coverage
VTE risk after bariatric surgery should be assessed
SEATTLE – Thromboelastometry can play a role in identifying bariatric surgery patients at risk for VTE.
Video
VIDEO: Screening ECG patch boosts AF diagnoses ninefold
ECG patches may provide an inexpensive and noninvasive way to screen for asymptomatic atrial fibrillation in high-risk people.
Conference Coverage
Few acutely ill hospitalized patients receive VTE prophylaxis
The results “imply that there is a significantly unmet need for effective VTE prophylaxis in both the inpatient and outpatient continuum of care...
Conference Coverage
ODYSSEY Outcomes trial redefines secondary cardiovascular prevention
ORLANDO – “I believe this trial is going to change practice.” – Valentin Fuster, MD
Video
Post-ACS death lowered in ODYSSEY Outcomes
ORLANDO – Mortality and major adverse cardiovascular events were cut 15%, but that’s not all.
Conference Coverage
Young diabetics are at sevenfold increased risk of sudden cardiac death
ANAHEIM, CALIF. – Danish national study is the first of its kind and found fivefold increased all-cause mortality.
Conference Coverage
Sex-triggered sudden cardiac arrest extremely rare
"Our take home message from this study is that sexual activity can be regarded as safe, even in cardiac patients."
